CJJD logo

China Jo-Jo Drugstores, Inc. (CJJD) Aktienanalyse

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Mit einem Kurs von $ ist China Jo-Jo Drugstores, Inc. (CJJD) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 42/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.

Zuletzt analysiert: 16. März 2026
42/100 KI-Bewertung

China Jo-Jo Drugstores, Inc. (CJJD) Gesundheitswesen & Pipeline-Uebersicht

CEOLei Liu
Mitarbeiter939
HauptsitzHangzhou, CN
IPO-Jahr2009

China Jo-Jo Drugstores, Inc. retails and distributes pharmaceutical and healthcare products in China, operating through retail drugstores, online platforms, wholesale, and herb farming. With a focus on traditional Chinese medicine (TCM) and Western medicine, the company operates retail pharmacies and online stores, facing competition in China's evolving healthcare market.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 16. März 2026

Investmentthese

China Jo-Jo Drugstores, Inc. presents a unique investment proposition within the Chinese healthcare market, characterized by its integrated approach to retail pharmacy, online sales, wholesale distribution, and herb farming. With a market capitalization of $0.01 billion and a P/E ratio of 1.20, the company's valuation metrics suggest potential undervaluation relative to its earnings. The company's profit margin of 8.5% and gross margin of 3.2% indicate areas for improvement in operational efficiency and cost management. Key growth catalysts include expanding its online pharmacy presence to capitalize on the growing e-commerce trend in China, and leveraging its TCM herb farming operations to meet increasing demand for traditional medicine. However, investors may want to evaluate the potential risks associated with operating in a highly regulated market, including evolving healthcare policies and pricing pressures. The company's beta of -0.15 suggests a low correlation with the broader market, potentially offering downside protection during market downturns.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Market capitalization of $0.01 billion, indicating a small-cap company with potential for growth.
  • P/E ratio of 1.20, suggesting the company may be undervalued compared to its earnings.
  • Profit margin of 8.5%, reflecting the company's profitability in the pharmaceutical retail sector.
  • Gross margin of 3.2%, indicating the percentage of total sales revenue that the company retains after incurring the direct costs associated with producing the goods and services it sells.
  • Operated 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, as well as 4 drugstores as of March 31, 2021, demonstrating a significant retail presence.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Established retail pharmacy network in China.
  • Integration of traditional Chinese medicine (TCM) with Western medicine.
  • Online pharmacy platform providing convenient access to healthcare products.
  • Herb farming operations ensuring a stable supply of TCM ingredients.

Schwaechen

  • Relatively small market capitalization compared to larger competitors.
  • Gross margin of 3.2% indicates potential inefficiencies.
  • Limited geographic diversification outside of China.
  • Dependence on regulatory approvals for pharmaceutical products.

Katalysatoren

  • Upcoming: Expansion of online pharmacy platform to increase market reach and sales.
  • Ongoing: Leveraging TCM expertise to develop new products and services for domestic and international markets.
  • Upcoming: Strategic partnerships with other healthcare providers or technology companies to enhance capabilities.
  • Ongoing: Efforts to improve operational efficiency and increase profit margins.

Risiken

  • Potential: Intense competition from other pharmaceutical retailers and online pharmacies.
  • Ongoing: Evolving healthcare regulations and pricing pressures in China.
  • Potential: Product recalls or safety concerns related to pharmaceutical products.
  • Potential: Fluctuations in the cost of raw materials for TCM herbs.
  • Ongoing: Dependence on regulatory approvals for pharmaceutical products.

Wachstumschancen

  • Expansion of Online Pharmacy Platform: China Jo-Jo Drugstores can capitalize on the increasing e-commerce penetration in China by expanding its online pharmacy platform. The Chinese online pharmacy market is projected to reach $49.7 billion in 2026, presenting a significant growth opportunity. By enhancing its online platform with a wider range of products, improved user experience, and strategic partnerships with e-commerce giants, the company can attract a larger customer base and drive online sales growth. Timeline: Ongoing.
  • Leveraging Traditional Chinese Medicine (TCM): With the growing popularity of TCM in China and globally, China Jo-Jo Drugstores can leverage its herb farming operations to meet the increasing demand for TCM products. The global TCM market is expected to reach $200 billion by 2025. By expanding its herb cultivation and processing capabilities, the company can ensure a stable supply of high-quality TCM ingredients and develop new TCM-based products for both domestic and international markets. Timeline: Ongoing.
  • Strategic Partnerships and Acquisitions: China Jo-Jo Drugstores can pursue strategic partnerships and acquisitions to expand its market reach and product offerings. Collaborating with other healthcare providers, pharmaceutical manufacturers, or technology companies can create synergies and enhance the company's competitive position. Acquiring smaller pharmacy chains or healthcare-related businesses can accelerate its expansion into new geographic areas or product categories. Timeline: Upcoming.
  • Enhancing Retail Pharmacy Network: While already having a retail presence, China Jo-Jo Drugstores can optimize its existing network of retail pharmacies by improving store layouts, product assortment, and customer service. Implementing data analytics to understand customer preferences and optimize inventory management can enhance sales and profitability. Expanding the range of healthcare services offered at its pharmacies, such as health screenings and consultations, can also attract more customers. Timeline: Ongoing.
  • Expanding Drug Wholesale Business: China Jo-Jo Drugstores can increase its revenue by expanding its drug wholesale business. By establishing partnerships with more pharmaceutical manufacturers and distributors, the company can increase the volume of products it distributes. Focusing on niche or specialized pharmaceutical products can also provide a competitive advantage. Timeline: Ongoing.

Chancen

  • Expansion of online pharmacy platform to reach more customers.
  • Leveraging TCM expertise to develop new products and services.
  • Strategic partnerships and acquisitions to expand market reach.
  • Increasing demand for healthcare products and services in China.

Risiken

  • Intense competition from other pharmaceutical retailers and online pharmacies.
  • Evolving healthcare regulations and pricing pressures in China.
  • Potential for product recalls or safety concerns.
  • Fluctuations in the cost of raw materials for TCM herbs.

Wettbewerbsvorteile

  • Established retail pharmacy network in China.
  • Integration of traditional Chinese medicine (TCM) with Western medicine.
  • Online pharmacy platform providing convenient access to healthcare products.
  • Herb farming operations ensuring a stable supply of TCM ingredients.

Ueber CJJD

Founded in 2003 and headquartered in Hangzhou, China, China Jo-Jo Drugstores, Inc. has evolved into a multifaceted healthcare company operating across various segments of the pharmaceutical industry. The company's primary business involves retailing and distributing pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices. These products are offered through its network of retail drugstores, operating under the Jiuzhou Grand Pharmacy name, and its online pharmacy platforms. The company also provides convenience products, such as consumable, seasonal, and promotional items. China Jo-Jo Drugstores distinguishes itself by integrating traditional and Western medical practices, offering on-site consultations with licensed doctors of Western medicine and TCM. This approach caters to a broad customer base seeking both conventional and alternative healthcare solutions. In addition to its retail operations, the company engages in drug wholesale, distributing third-party pharmaceutical products to trading companies. It also cultivates and wholesales herbs used for TCM, further diversifying its revenue streams. As of March 31, 2021, China Jo-Jo Drugstores operated 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, along with 4 additional drugstores, demonstrating its established presence in the Chinese pharmaceutical retail market.

Was das Unternehmen tut

  • Operates retail drugstores under the Jiuzhou Grand Pharmacy name.
  • Sells prescription and over-the-counter drugs.
  • Offers nutritional supplements and traditional Chinese medicines (TCM).
  • Provides personal and family care products and medical devices.
  • Operates an online drugstore retailing OTC drugs and nutritional supplements.
  • Sells products through third-party online platforms.
  • Distributes third-party pharmaceutical products to trading companies.
  • Cultivates and wholesales herbs used for TCM.

Geschaeftsmodell

  • Retail sales of pharmaceutical products through physical stores.
  • Online sales of pharmaceutical products through its online pharmacy.
  • Wholesale distribution of pharmaceutical products to other companies.
  • Cultivation and sale of herbs used in traditional Chinese medicine.

Branchenkontext

China Jo-Jo Drugstores operates within the rapidly evolving Chinese healthcare market, which is characterized by increasing demand for pharmaceutical products and healthcare services. The market is driven by factors such as an aging population, rising disposable incomes, and growing awareness of health and wellness. The competitive landscape includes both domestic and international players, ranging from large pharmaceutical manufacturers to retail pharmacy chains. China Jo-Jo Drugstores differentiates itself through its integrated business model, combining retail pharmacy, online sales, wholesale distribution, and herb farming. The company's focus on traditional Chinese medicine (TCM) also provides a unique selling proposition in a market where TCM remains highly valued.

Wichtige Kunden

  • Individual consumers seeking prescription and over-the-counter medications.
  • Customers interested in nutritional supplements and personal care products.
  • Patients seeking traditional Chinese medicine (TCM) remedies.
  • Trading companies purchasing pharmaceutical products for distribution.
KI-Zuversicht: 80% Aktualisiert: 16. März 2026

Finanzdaten

Chart & Info

China Jo-Jo Drugstores, Inc. (CJJD) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CJJD.

Kursziele

Wall-Street-Kurszielanalyse fuer CJJD.

MoonshotScore

42/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von CJJD auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Fuehrung: Lei Liu

CEO

Lei Liu is the Chief Executive Officer of China Jo-Jo Drugstores, Inc. His background encompasses extensive experience in the pharmaceutical retail sector in China. Details regarding his specific educational background and prior roles are not available. As CEO, he is responsible for overseeing the company's strategic direction, operational performance, and financial results. He manages a workforce of 939 employees.

Erfolgsbilanz: Since becoming CEO, Lei Liu has focused on expanding the company's online presence and leveraging its traditional Chinese medicine (TCM) capabilities. Specific milestones and achievements under his leadership are not available, but the company continues to operate in a competitive market. He is responsible for navigating the evolving regulatory landscape and driving growth in the Chinese healthcare market.

Was Anleger ueber China Jo-Jo Drugstores, Inc. (CJJD) wissen wollen

What are the key factors to evaluate for CJJD?

China Jo-Jo Drugstores, Inc. (CJJD) currently holds an AI score of 42/100, indicating low score. Key strength: Established retail pharmacy network in China.. Primary risk to monitor: Potential: Intense competition from other pharmaceutical retailers and online pharmacies.. This is not financial advice.

How frequently does CJJD data refresh on this page?

CJJD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven CJJD's recent stock price performance?

Recent price movement in China Jo-Jo Drugstores, Inc. (CJJD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established retail pharmacy network in China.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider CJJD overvalued or undervalued right now?

Determining whether China Jo-Jo Drugstores, Inc. (CJJD) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying CJJD?

Before investing in China Jo-Jo Drugstores, Inc. (CJJD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding CJJD to a portfolio?

Potential reasons to consider China Jo-Jo Drugstores, Inc. (CJJD) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Established retail pharmacy network in China.. Additionally: Integration of traditional Chinese medicine (TCM) with Western medicine.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of CJJD?

Yes, most major brokerages offer fractional shares of China Jo-Jo Drugstores, Inc. (CJJD) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track CJJD's earnings and financial reports?

China Jo-Jo Drugstores, Inc. (CJJD) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CJJD earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Information is based on available data and may be subject to change.
  • AI analysis is pending for CJJD, which may provide further insights.
  • The Chinese healthcare market is subject to regulatory and economic uncertainties.
Datenquellen

Popular Stocks